WAIKOLOA, Hawaii — Treatment with monthly aflibercept resulted in less progression of retinal nonperfusion compared with quarterly aflibercept in patients with proliferative diabetic retinopathy, according to a speaker here.
“Overall, what is clear is that nonperfusion progresses despite an apparent improvement in diabetic retinopathy scores in these patients,” SriniVas Sadda, MD, said at Retina 2022 on behalf of the investigators of the RECOVERY trial.
RECOVERY trial researchers investigated the effect of aflibercept 2 mg on retinal nonperfusion in patients with proliferative